CADIAN CAPITAL MANAGEMENT, LP - BLUEPRINT MEDICINES CORP ownership

BLUEPRINT MEDICINES CORP's ticker is BPMC and the CUSIP is 09627Y109. A total of 216 filers reported holding BLUEPRINT MEDICINES CORP in Q3 2023. The put-call ratio across all filers is 2.45 and the average weighting 0.2%.

Quarter-by-quarter ownership
CADIAN CAPITAL MANAGEMENT, LP ownership history of BLUEPRINT MEDICINES CORP
ValueSharesWeighting
Q3 2022$96,162,000
-5.8%
1,459,431
-27.8%
5.62%
-18.5%
Q2 2022$102,062,000
-16.8%
2,020,629
+5.2%
6.89%
+12.5%
Q1 2022$122,736,000
+154.3%
1,921,347
+326.3%
6.13%
+130.9%
Q4 2021$48,270,000
-55.4%
450,657
-57.2%
2.65%
-35.0%
Q3 2021$108,177,000
-6.9%
1,052,203
-20.4%
4.08%
-20.9%
Q2 2021$116,223,000
+30.8%
1,321,313
+44.6%
5.16%
+57.0%
Q1 2021$88,839,000
-25.2%
913,702
-13.8%
3.29%
+7.7%
Q4 2020$118,817,000
-52.3%
1,059,450
-60.6%
3.05%
-62.4%
Q3 2020$249,072,000
+166.5%
2,686,856
+124.3%
8.11%
+108.8%
Q2 2020$93,443,000
+30.3%
1,197,989
-2.3%
3.88%
+10.1%
Q1 2020$71,702,000
-54.5%
1,226,096
-37.7%
3.53%
-49.4%
Q4 2019$157,660,000
+51.3%
1,968,038
+38.7%
6.96%
+40.5%
Q3 2019$104,232,000
+111.2%
1,418,704
+171.1%
4.96%
+122.6%
Q2 2019$49,359,000
+208.3%
523,261
+161.6%
2.23%
+256.2%
Q1 2019$16,010,000
-26.8%
200,000
-36.3%
0.62%
-38.9%
Q3 2017$21,874,000
-5.6%
313,965
-31.3%
1.02%
-9.3%
Q2 2017$23,161,000
+231.2%
457,102
+161.4%
1.13%
+236.7%
Q1 2017$6,994,000174,9000.34%
Other shareholders
BLUEPRINT MEDICINES CORP shareholders Q3 2023
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 581,768$25,487,2569.57%
Casdin Capital, LLC 1,477,800$64,742,4185.02%
Nextech Invest Ltd. 188,228$8,246,2693.28%
DAFNA Capital Management LLC 261,235$11,444,7053.22%
Rock Springs Capital Management LP 1,891,510$82,867,0531.99%
HealthCor Management, L.P. 30,000$1,314,3001.20%
EFG Asset Management (North America) Corp. 110,853$4,766,6791.07%
Novo Holdings A/S 370,000$16,209,7001.01%
SECTORAL ASSET MANAGEMENT INC 115,900$5,077,5790.98%
EMERALD MUTUAL FUND ADVISERS TRUST 305,709$13,393,1110.83%
View complete list of BLUEPRINT MEDICINES CORP shareholders